King Ups Medicaid Rebate Underpayment Estimate To $65 Mil.; CEO To Depart
Executive Summary
King Pharmaceuticals is raising its estimated Medicaid rebate underpayments by $18.9 mil. to $65.4 mil. following the completion of an internal audit, CFO Jim Lattanzi said during a Feb. 19 conference call
You may also be interested in...
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan
Bristol And SEC Define “Normal” Inventory Levels As One Month
Bristol-Myers Squibb and the Securities & Exchange Commission have agreed to define "normal" wholesale inventory levels as approximately one-month worth of product on hand